Economic burden of severe asthma treatment: A real-life study.

ABSTRACT:

Background

Individuals with severe asthma represent 5%-10% of the general asthmatic population. Despite the use of biologic drugs during clinical management, inadequate control of the disease has translated into high economic impact. In Mexico, however, these costs have not yet been assessed.

Methods

A retrospective cohort study was carried out in 2018 and 2019 at Regional Hospital Lic. Adolfo López Mateos, ISSSTE. The assessment of direct costs included pharmacological treatment, clinical tests, days of hospitalization, admissions to the emergency room, and scheduled consultations. The evaluation involved 2 groups of patients-with controlled severe asthma (CSA) and uncontrolled severe asthma (UCSA)-according to presence of exacerbations.

Results

60 patients (1

SUBMITTER: Lopez-Tiro J 

PROVIDER: S-EPMC9260620 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature